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Abstract 
 
Objective(s)  
The role of therapeutic drug monitoring (TDM) in patient care has grown rapidly since its introduction three 
decades ago. The aim of present study was to evaluate the possible relationship between serum levels and the 
clinical response of valproic acid (VPA).  
Materials and Methods  
In the present study we evaluated a homogeneous group of adult patients receiving VPA monotherapy.               
A total of 18 epileptic patients who fulfilled inclusion and exclusion criteria were entered this prospective 
study. Steady state trough plasma concentration was determined by fluorescence polarization immunoassay 
(FPIA). The correlation between therapeutic response and VPA serum concentration was evaluated.   
Results  
Mean VPA dose and mean total VPA plasma  concentrations  were  8.35±1.49  mg/kg/day  and                 
50.40±4.18 µg/ml respectively. Mean VPA clearance was 8.84±4.43 (ml/kg/h). Plasma levels within the 
therapeutic range were found in 33% of epileptic patients. Plasma levels were below the therapeutic range in 
67% of study population. Of patients 75% and 17% with sub-therapeutic levels achieved complete control 
and partial control respectively.  
Conclusion  
Poor correlation was found between the plasma concentration of VPA and its therapeutic effects. Therefore, 
this study showed that TDM of VPA will be useful only when individuals are non-responsive to treatment or 
vulnerable to adverse reactions with standard doses. 
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Introduction 
Therapeutic drug monitoring (TDM) or the 
measurement of drug concentrations in 
plasma, serum or blood, aims to improve 
clinical activity, avoid toxicity, and reduce the 
costs of drug treatment. Specific conditions for 
TDM to be reasonably applied include the 
availability of a validated assay, a considerable 
inter-individual pharmacokinetic variability,          
a high correlation between drug concentration 
and  toxicity,  and  a  narrow  therapeutic               
index (1). Because clinical effects are more 
closely related to drug levels than dose, 
clinicians can use therapeutic drug monitoring 
to optimize dosage decisions, in order to 
maximize efficacy and prevent toxicity (2). In 
the last 10-20 years therapeutic monitoring of 
antiepileptic drugs (AEDs) has had a major 
impact on epilepsy management due to 
enhance understanding of AEDs 
pharmacokinetics (3). This article discusses 
TDM for valproic acid (VPA) which has the 
widest spectrum of activity among the 
available antiepileptic drugs. Valproic acid is 
chemically related to free fatty acids. This 
drug is one of the most widely used AEDs in 
treatment of both generalized and partial 
seizures in adults and children. The capability 
of treating many type of seizure with a single 
anticonvulsant has resulted in the wide-spread 
use of VPA particularly in children (4). 
Furthermore, it is increasingly used for therapy 
of bipolar and schizoaffective disorders, 
neuropathic pain and for prophylactic 
treatment of migraine headache (5, 6). 
Monitoring of VPA is helpful when its toxicity 
and efficacy are doubtful. Because of 
significant inter-individual pharmacokinetic 
variability and concentration-dependent, 
plasma protein binding pharmacokinetic of 
VPA, the clearance of VPA is not a constant as 
it is the case for linear pharmacokinetics and is 
reported to be concentration or dose-dependent 
(3, 4, 7). In addition, clinical effects of VPA 
bear a relatively close relation to serum drug 
concentration. Its appropriate serum 
concentration depends on different factors 
such as age, total body weight, VPA dosage 
and co-administration of the other drugs which 
affect pharmacokinetics of VPA. 
Determination of serum concentration of VPA 
is valuable to improve clinical decisions and 
avoid adverse drug reactions (ADRs) (4, 8, 9). 
It also provide clinicians with important 
information for making quantitative 
therapeutic decision, that is, titration of drug 
dose  according to the individual patients, thus 
avoiding ADRs  (10). Therefore, in the the 
present study we investigated the TDM of 
VPA in epileptic patients. 
 
Materials and Methods 
Patients 
This study was carried out prospectively 
during the course of a therapeutic drug 
monitoring program in the Psychiatric and 
Neurologic  Clinic of Ebn Sina and Ghaem 
hospitals of Mashhad University of Medical 
Sciences in Iran between July 2005 and April 
2006. All of the patients fulfilled the following 
inclusion criteria: a) Receiving a constant dose 
of VPA at least for 5 days. b) Taking VPA 
alone or with other drugs which have no effect 
on VPA pharmacokinetic. Exclusion criteria 
were: a) Patients with abnormal renal function 
tests. b) Patients with abnormal liver function 
tests. Whenever a blood sample was taken, all 
relevant demographic data (e.g. age, gender, 
body weight), and medication details 
(sampling time, duration of therapy, 
concurrent medication and adverse drug 
reactions) were recorded. Therapeutic 
response also was evaluated when complete 
control referred to patients free of seizures and 
partial control referred to reduction in 
frequency and intensity of seizures. In 
addition, several laboratory tests (CBC, BUN, 
ALT, and AST) were performed. 
    
Blood sampling and drug assays 
Trough Serum samples were taken before the 
administration of the morning dose. 
Fluorescence polarization immunoassay 
(FPIA) method was used for determination of 
the serum VPA concentration. An acceptable 
VPA assay calibration curve should meet the 
following criteria: Polarization Error (PERR) 
of -2.00 to +2.00 for all calibration and Root 
Mean Squared Error (RMSE) less than or 
equal to 1.00. Descriptive analysis was carried 
out  by  SPSS  software  for  windows                 
(version 11.5, USA).   
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Results 
Characteristics of the study populations 
The study population consisted of 18 epileptic 
patients. Demographic and medication details 
for the patients are summarized in Table 1. All 
of the patients were on monotherapy. 
 
Table 1.  Characteristics of the study population 
18 
32% 
68% 
28.64±9.22
1 
63.95±6.82 
8.35±1.49 
50.40±24.18 
8.84±4.43 
Patients (n)  
Male 
Female                                                
Age (yr)                                              
Total body weight (kg)                       
VPA dosage (mg/kg/day)                   
Serum VPA concentration (µg/ml)    
VPA CL /F (ml/kg/hr) 
1. Mean±SD 
 
VPA plasma level fluctuation in patients 
Our results showed high inter-individual 
variability in VPA serum level (Table 2). 
 
Table 2. Mean of inter-individual variability in VPA 
serum concentrations  
CV% 
38.96% 
45.75% 
14.25% 
VPA dose 
400 (mg/day) 
600 (mg/ml) 
800 (mg/ml) 
 
TDM of VPA 
The high portion of epileptic patients in whom 
VPA level was in sub-therapeutic range 
showed the partial or complete response and 
34% of patients who had a VPA level in 
therapeutic range didn’t show complete 
response (Figure 1 and Table 3). 
 
Table 3. TDM of VPA 
Therapeutic rang 
Complete response 
Partial response 
No response 
 
Sub-therapeutic rang 
Complete response 
Partial response 
No response 
 
Toxic level 
33% 
66% 
17% 
17% 
 
67% 
75% 
17% 
8% 
 
0 
 
Discussion 
Our results indicate that in a large number of 
epileptic patients (67%), VPA levels were in 
the sub-therapeutic range whereas 75% and 
17% of these patients achieved complete 
control and partial control respectively. In our 
experiments we found that a new therapeutic 
range for VPA in the Iranian population 
should be determined. 
Therapeutic range
66%
17%
17%
Complete
response
Partial response
No response
 
 
Sub-therapeutic range
75%
17%
8%
Complete
response
Partial response
No response
 
 
Figure 1. The ratio of patients with partial, complete or 
no response which their VPA levels are in therapeutic or 
sub-therapeutic ranges.  
 
 
 
VPA is used increasingly in neurology for 
the treatment of epilepsy, patients with bipolar 
mood disorders and other neuralgia. Clinical 
effects are more closely related to drug levels 
than to dose. TDM is particularly useful  in 
determination of drug levels and identification 
of therapeutic failure due to under dosage, and 
-even in the presence of optimal dosage- for 
identification of serious toxicity, inter-
individual pharmacokinetic variability (Rapid 
or Slow metabolism of drug) and detection of 
pharmacokinetic interactions (10). VPA shows 
diurnal variation in serum concentration. 
Therefore, the serum samples should be 
collected at the same time of days, trough 
levels are preferred (11).  
In spite of high fluctuation in serum level of 
VPA (Table 2) indicating the TDM of VPA for 
defining the therapeutic range of VPA, the 
TDM results showed that there was no 
significant correlation between VPA serum 
level and the therapeutic response.    
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Conclusion 
This study suggests that the therapeutic range 
should be defined for Iranian population. In 
addition, based on the finding of the present 
study, despite TDM usefulness in therapy by 
determination of sub-therapeutic levels in a 
time course, TDM of VPA will be useful only 
when individuals are non-responsive to 
treatment or vulnerable to adverse reactions 
with standard doses. 
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